Artera Announces Positive Results Around Its Multimodal Artificial Intelligence (MMAI) Prognostic Biomarker
Press Release
Announcements
How AI can support the American Cancer Society’s IMPACT Initiative
Andre Esteva, Co-founder and CEO of Artera, discusses how AI can support the ACS' IMPACT initiative and other possibilities in the healthcare industry.
MM+M Article
Our very own Tim Showalter will be presenting our science at Biomarkers 2023 in Manchester, UK from February 27-28.
Pathology-Based Deep Learning Tools to Personalize Treatment Decisions: ArteraAI Prostate Test Development & Validation
Presented by: Tim Showalter, MD, MPH (Monday, February 27, 2023 at 9:45 AM EST)
Our science was presented at the 2023 ASCO Genitourinary Cancers Symposium in San Francisco from February 16-18.
Patient-Level Data Meta-Analysis of a Multi-Modal Artificial Intelligence (MMAI) Prognostic Biomarker in High-Risk Prostate Cancer: Results From Six NRG/RTOG Phase IIIRandomized Trials
Presented by: Daniel Spratt, MD (Thursday, February 16, 2023 at 8:42 AM PST)
Our science was presented at the 2022 ASTRO Annual Meeting in San Antonio from October 23-26.
Presidential Symposium: The State of the Art in Digital Pathology and AI: Progress in Prostate Cancer
Presented by: Osama Mohamad, MD (Sunday, October 23, 2022 at 12:15 PM)
UroToday Article
Plenary Session: Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital Histopathology
Presented by: Jonathan D. Tward, MD, PhD, FASTRO (Monday, October 24, 2022 at 1:46 PM)
UroToday Article
Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials.
Prostate cancer is the most frequent cancer in men and a leading cause of cancer death. Determining a patient's optimal therapy is a challenge, where oncologists must select a therapy with the highest likelihood of success and the lowest likelihood of toxicity. International standards for prognostication rely on non-specific and semi-quantitative tools, commonly leading to over- and under-treatment. Tissue-based molecular biomarkers have attempted to address this, but…
Nature DM
Artera Launches with $90 Million in Funding to Personalize Cancer Therapy With Multimodal AI
Artera, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, launched publicly today with $90M in funding.
Our very own Tim Showalter presented our science at Biomarkers 2023 in Manchester, UK from February 27-28.
Pathology-Based Deep Learning Tools to Personalize Treatment Decisions:
ArteraAI Prostate Test Development & Validation
Presented by: Tim Showalter, MD, MPH (Monday, February 27, 2023 at 9:45 AM EST)
MMAI Model More Accurately Predicts Outcomes of High-Risk Prostate Cancer
Jessica Nye from Cancer Therapy Advisor discusses key findings, presented by Daniel Spratt, MD at ASCO GU 2023, demonstrating that Artera’s prognostic MMAI biomarker can more accurately estimate long-term outcomes compared to standard clinicopathologic markers for patients with high-risk prostate cancer.
Dr. Spratt Highlights the Validation of an MMAI Prognostic Biomarker for Prostate Cancer
Urology Times features a video of Daniel Spratt, MD discussing results demonstrating successful validation of Artera’s MMAI prognostic biomarker in high-risk prostate cancer.
Multimodal AI Biomarker May Help Personalize Decision-Making in High-Risk Prostate Cancer
Mark Leiser from HemOnc Today discusses results from Artera’s prognostic MMAI model that were presented by Daniel Spratt, MD at ASCO GU 2023. The article includes a perspective from Eric Horwitz, MD, FABS, FASTRO.
Artera Announces Positive Results Around Its Multimodal Artificial Intelligence (MMAI) Prognostic Biomarker
Our science was presented at the 2023 ASCO Genitourinary Cancers Symposium in San Francisco from February 16-18.
Patient-Level Data Meta-Analysis of a Multi-Modal Artificial Intelligence (MMAI) Prognostic Biomarker in High-Risk Prostate Cancer: Results From Six NRG/RTOG Phase III
Randomized Trials
Presented by: Daniel Spratt, MD (Thursday, February 16, 2023 at 8:42 AM PST)
Artera Announces Positive Results Around Its Multimodal Artificial Intelligence (MMAI) Prognostic Biomarker
How AI can support the American Cancer Society’s IMPACT Initiative
Andre Esteva, Co-founder and CEO of Artera, discusses how AI can support the ACS’ IMPACT initiative and other possibilities in the healthcare industry.
Our science was presented at the 2022 ASTRO Annual Meeting in San Antonio from October 23-26.
Presidential Symposium: The State of the Art in Digital Pathology and AI: Progress in Prostate Cancer
Presented by: Osama Mohamad, MD (Sunday, October 23, 2022 at 12:15 PM)
UroToday Article
Plenary Session: Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital Histopathology
Presented by: Jonathan D. Tward, MD, PhD, FASTRO (Monday, October 24, 2022 at 1:46 PM)
UroToday Article